{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:47:03Z","timestamp":1773110823652,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clml.2023.04.005","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T12:01:05Z","timestamp":1682337665000},"page":"606-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-9662","authenticated-orcid":false,"given":"Amin","family":"Azem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Caddell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leidy","family":"Isenalumhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Pinilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-6088","authenticated-orcid":false,"given":"Hayder","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.04.005_bib0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.005_bib0002","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Au","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.005_bib0003","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.005_bib0004","first-page":"55","article-title":"Characteristics of nasal T\/NK-cell lymphoma among Brazilians","volume":"49","author":"Altemani","year":"2002","journal-title":"Neoplasma"},{"key":"10.1016\/j.clml.2023.04.005_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.oraloncology.2006.03.011","article-title":"Extranodal NK\/T-cell lymphoma, nasal type","volume":"43","author":"Al-Hakeem","year":"2007","journal-title":"Oral Oncol"},{"key":"10.1016\/j.clml.2023.04.005_bib0006","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00428-001-0545-1","article-title":"Classification of cell lineage and anatomical site, and prognosis of extranodal T-cell lymphoma \u2014 natural killer cell, cytotoxic T lymphocyte, and non-NK\/CTL types","volume":"440","author":"Ohshima","year":"2002","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clml.2023.04.005_bib0007","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.04.005_bib0008","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.clml.2020.10.006","article-title":"Extranodal NK\/T Cell Lymphoma: evidence-based review of safety and toxicity of the available regimens","volume":"21","author":"Saeed","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2023.04.005_bib0009","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2141.2005.05694.x","article-title":"Selective apoptosis of natural killer-cell tumours by l-asparaginase","volume":"130","author":"Ando","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2023.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2023.04.005_bib0011","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.04.005_bib0012","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1080\/10428194.2016.1180689","article-title":"Encouraging experience in the treatment of nasal type extra-nodal NK\/T-cell lymphoma in a non-Asian population","volume":"57","author":"Qi","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.04.005_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14737140.2019.1549992","article-title":"Defining the toxicity of current regimens for extranodal NK\/T cell lymphoma: a systematic review and metaproportion","volume":"19","author":"Pokrovsky","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2023.04.005_bib0014","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1080\/10428194.2020.1811864","article-title":"Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population","volume":"61","author":"Ghione","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:44Z","timestamp":1761871364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2152265023001325"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}